Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Clinical Medicine of China ; (12): 367-369, 2013.
Artigo em Chinês | WPRIM | ID: wpr-432029

RESUMO

Objective To observe the effect of Rosuvastatin on apolipoprotein A1 (Apo A1),apolipoprotein B(Apo B) and Apo B/Apo A1 patients with acute coronary syndrome.Methods One hundred and fifty hospitalized patients with acute coronary syndrome were randomly divided into three groups,A group (Rosuvastatain,5 mg/d),B group (Rosuvastatain,10 mg/d),and C group (Simvastatin,20 mg/d).Before and at 4,8 weeks after treatments tested the three groups' cholesterol (TC),glycerin(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol (LDL-C),Apo A1,Apo B.Compare the blood lipids aforementioned before and after treatments in three groups.Results (1) After treatments for 4 weeks,TC,LDLC in three groups are significant lower than before (P < 0.05).After treatments for 8 weeks,TC,LDL-C,Apo B,Apo B/Apo A1 of three groups are lower than before and HDL-C 、Apo A1 is higher than before (P < 0.05).(2)After treatments for 8 weeks,comparing to A and C groups,TC,LDL-C,Apo B,Apo B/Apo A1 in B group were lower while HDL-C、Apo A1 were higher (P < 0.05).(3)The incidences of liver damage has no significant differences among three groups (x2 =1.25,P > 0.05).Conclusion Effects of 10 mg/d rosuvastatain were better than 5 mg/d rosuvastatain and 20 mg/d simvastatin in increasing Apo A1 and decreasing Apo B,Apo B/Apo A1,and then effectively control of ACS.

2.
Chinese Journal of Geriatrics ; (12): 104-108, 2011.
Artigo em Chinês | WPRIM | ID: wpr-413889

RESUMO

Objective To investigate the effect of immune modulation therapy on heart function and cytokines in elder patients with chronic heart failure (CHF). Methods The 96 patients aged 60-78 years with New York Heart Association(NYHA)functional. class Ⅱ-Ⅳ CHF were randomly divided into two groups: CHF treatment group received regular therapy and thymopetidum and CHF control group received regular therapy. Another 45 healthy individuals aged 60-80 years were involved as normal control. The ejection faction of left ventricle (LVEF), inflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), anti-inflammatory cytokine interleukin-10 (IL-10), plasma high sensitive C-reactive protein (hsCRP), plasma brain natrium peptide (BNP)and Minnesota Living with Heart Failure Questionnaire (LHFQ) assessment were tested before therapy, 15 days and 75 days after treatment. Results (1) Before therapy, compared with normal control group, the levels of TNF-α, IL-1β, TNF-α/IL-10 ratio, BNP, hsCRP and LHFQ were significantly increased (P < 0. 05 or P < 0. 01 ), and the levels of IL-10, LVEF were markedly decreased (P<0.01) in the patients of CHF treatment group and CHF control group. While no difference between the two CHF groups was observed. (2) After the first course of treatment,compared with CHF control group, the levels of IL-10 were increased (P<0. 01), while the levels of TNF-α, IL-1β, BNP and hsCRP were decreased (P<0.05 or P<0.01) in CHF treatment group. The level of LVEF was increased, TNF-α/IL-10 ratio (4.84 ±0. 53 vs. 5.28±0. 66) and LHFQ were decreased even though there was no significant difference between the two groups. (3) After the second course of treatment, compared with CHF control group, the levels of IL-10 and LVEF were increased (P<0. 05 or P<0.01), while the level of TNF-α, IL-1β, TNF-α/IL-10 ratio (4.55±0. 69 vs. 5.18±0.38), BNP, hsCRP and LHFQ were decreased (P<0.05 or P<0.01) in CHF treatment group. Conclusions Thymopetidum, as an immunemodulating agent, might regulate the equilibrium of cytokines and improve the heart function of patients with CHF, indicating that immune modulation therapy might improve the treatment strategy for CHF patients.

3.
Chinese Journal of Geriatrics ; (12): 323-326, 2011.
Artigo em Chinês | WPRIM | ID: wpr-413857

RESUMO

Objective To investigate the effects of Shexiangbaoxin pills (SXBXP) on the serum levels of T helper type 1 (Th1) cytokines including tumor necrosis factor-a (TNF-α),interferon-γ(IFN-γ) and T helper type 2 (Th2) cytokines incloding interleukin-4 (IL-4),interleukin-10 (IL-10)in rats with chronic heart failure (CHF).Methods The CHF models were established by left anterior descending coronary artery ligation.Fifty-four Wistar rats were randomly divided into six groups:control group,sham operation group,CHF model group,small dose SXBXP group,large dose SXBXP group and positive medicine group.Heart function was examined by echocardiography before and after therapy,the TNF-α and IL-10 levels were measured by radioimmunoassay,IFN-γ and IL-4 levels were measured by enzyme linked immunosorbent assay (ELISA).Results (1) Before therapy,there was no significant difference between control group and sham operation group in ejection fraction of left ventricle (LVEF).Compared with control group and sham operation group,the levels of LVEF were significantly decreased in CHF model group,small dose SXBXP group,large dose SXBXP group and positive medicine group (all P<0.01).(2) After therapy,compared with sham operation group,the serum levels of TNF-α and IFN-γ were markedly increased,and IL-4 and IL-10 were significantly decreased in CHF model group (all P<0.01 ).Compared with CHF model group,LVEF was significantly improved,serum levels of TNF-α and IFN-γ were markedly decreased,IL-4 and IL-10 were markedly increased in large dose SXBXP group (all P<0.05).In small dose SXBXP group,serum levels of IFN-γ were markedly decreased and IL-10 were markedly increased (all P<0.05).In positive medicine group,serum levels of TNF-α and IFN-γ were markedly decreased and IL-10 were markedly increased (all P<0.05).In small dose SXBXP group and positive medicine group,serum levels of IL-4 increased and LVEF decreased,even though there was no significant difference compared with CHF model group.Conclusions The SXBXP therapy of rats with CHF induced by myocardial infarction improves the heart function,decreases the serum levels of TNF-α and IFN-γ,and increases serum levels of IL-4 and IL-10.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA